[Front line of management of hyperphosphatemia in hemodialysis patients].
Management of hyperphosphatemia in hemodialysis patients is very important to prevent progress of renal hyperparathyroidism or ectopic calcification. Sevelamer hydrochloride is a Ca and Al free phosphate binder, and reduces serum phosphorus level, without any influence on serum Ca level, and Ca-P products. This compound is expected to reduce the incidence of arterial calcification, and improve the QOL (quality of life) of hemodialysis patients.
Yumita
Shigeru
S
Department of nephroendocrinology, Kojinkai Central Hospital.
D002114:Calcinosis / Q000209:etiology / Q000517:prevention & control; D002118:Calcium / Q000097:blood; D004852:Epoxy Compounds / Q000627:therapeutic use*; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000209:etiology / Q000517:prevention & control; D007475:Ion Exchange Resins / Q000627:therapeutic use*; D007676:Kidney Failure, Chronic / Q000150:complications; D010758:Phosphorus / Q000097:blood*; D010760:Phosphorus Metabolism Disorders / Q000188:drug therapy* / Q000209:etiology; D011073:Polyamines; D011095:Polyethylenes / Q000627:therapeutic use*; D006435:Renal Dialysis / Q000009:adverse effects*; D000069603:Sevelamer; D014652:Vascular Diseases / Q000209:etiology / Q000517:prevention & control
D004852:Epoxy Compounds; D007475:Ion Exchange Resins; D011073:Polyamines; D011095:Polyethylenes; D010758:Phosphorus; D000069603:Sevelamer; D002118:Calcium